In the company’s news yesterday,
Nutra Pharma Corp. announced that its drug discovery subsidiary ReceptoPharm published the positive results of its recent pain study in Toxicon, the official journal of the International Society on Toxinology. The study examined RPI-78, ReceptoPharm’s leading drug candidate for the treatment of pain, revealing that its pain reducing effects lasted four-times as long as morphine, without the associated negative side effects of opioid-based pain relievers.
“The results from this study provide a significant step forward in the development of an effective and non-narcotic treatment for moderate to severe pain,” commented Dr. Paul Reid, CEO of ReceptoPharm. “With these results in hand, we believe that RPI-78 could become the first non opioid-based analgesic dedicated to treating Stage II and Stage III pain,” he added.
The ReceptoPharm study revealed that RPI-78 has a dose-dependent inhibitory effect on the electrical activity of Pf neurons in male rats. As per the study, RPI-78 lasted for at least 2 hours, compared to morphine, which lasted about 30 minutes. Molecularly, RPI-78 was observed to be 4,000 times more potent than morphine. Additionally, the study observed increased serotonin levels in subjects treated with RPI-78.
Rik J. Deitsch, Chairman and CEO of Nutra Phrarma Corp. stated, “While many opioid-based drugs provide fast and temporary pain relief, the negative side effect profiles and addictive properties of these medicines make them extremely difficult to administer. Because RPI-78 is more effective than morphine and does not produce these negative side effects, we believe that this drug could become the therapy of choice among hospitals and physicians in the near future.”
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 750,000+ subscribers that receive The Daily Stock Newsletters.
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
